Abstract
Recombinant interleukin 2 (rIL2) was administered to a patient with Wiskott-Aldrich syndrome for the treatment of an intractabel facial herpetiforme lesion. This treatment appeared to be effective in suppressing the virus activity. At the same time, a transient improvement of the chronic eczematoid dermatitis was observed. During rIL2 administration, the CD3+ and CD4+ subsets of peripheral blood lymphocytes increased in number. These changes might play an important role in the induction of anti-viral immunity and in the improvement of dermatits.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- rIL2:
-
recombinant Interleukin 2
- WAS:
-
Wiskott-Aldrich syndrome
References
Bich-Thuy LT, Dukovich M, Peter NJ, Fauci AS, Kehrl JH, Green WC (1987) Direct activation of human resting T cells by IL2: the role of an IL2 receptor distinct from the Tac protein. J Immunol 139:1550–1556
Chien CH, Hsieh K-H (1990) Interleukin-2 immunotherapy in children. Pediatr 86:937–943
Fisher SJ, Cui TY, Zhang L, Hartman L, Grahl K, Zhang G-Y, Tarpey J, Damsky CH (1989) Adhessive and invasive interaction of human cytotrophoblast cells in vitro. J Cell Biol 109:891–902
Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human preipheral blood lymphocytes. J Exp Med 155:1823–1841
Henney CS, Kuribayashi K, Kern DE, Gillis S (1981) Interleukin-2 augments natural killer cell activity. Nature 291:335–338
Miyasaka N, Darnell B, Baron S, Talal N (1984) Interleukin-2 enhances natural killing of normal lymphocytes. Cell Immunol 84:154–162
Ochs HD, Slichter SJ, Harker LA, Von Behrens WE, Clark RA, Wedgwiid RJ (1980) The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets. Blood 55:243–256
Pahwa R, Chatila T, Pahwa S, Paradise C, Day NK, Geha R, Schwartz SA, Slade H, Oyaizu N, Good RA (1989) Recombinant interleukin 2 therapy in severe combined immunodeficiency disease. Proc Natl Acad Sci 86:5069–5073
Rosenberg SA, Lotze MT, Muul LM, Chnag AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokineactivated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316:889–897
Rouse BT, Miller LS, Turtinen L, Moore RN (1985) Augmentation of immunity to herpes simplex virus by in vivo administration of interleukin2. J Immunol 134:926–930
Schmid DS (1988) The human MHC-restricted cellular response to herpes simplex virus type 1 is mediated by CD4+, CD8- T cells and is resticted to the DR region of the MHC complex. J Immunol 140:3610–3616
Sharon M, Siegel JP, Tosato G, Yodoi J, Gerrard TL, Leonard WJ (1988) The human interleukin 2 receptor chain (P70) Direct identification, partial purification, and patterns of expression on peripheral blood mononuclear cells. J Exp Med 167:1265–1270
Siegel JP, Sharon M, Smith PL, Leanard WJ (1987) The IL-2 receptor chain (P70): role in mediating signals for LAK, NK, and proliferative activities. Science 238:75–78
Torpey DJ, Lindsley MD, Rinald CR (1989) HLA-restricted lysis of herpes simplex virus-infected monocytes and macrophages mediated by CD4+ and CD8- T lymphocytes. J Immunol 142:1325–1332
Trinchieri G, Kobayashi MM, Clark SC, Seehra J, London L, Perussia B (1984) Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med 160:1147–1169
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Azuma, H., Sakata, H., Saijyou, M. et al. Effect of interleukin 2 on intractable herpes virus infection and chronic eczematoid dermatitis in a patient with Wiskott-Aldrich syndrome. Eur J Pediatr 152, 998–1000 (1993). https://doi.org/10.1007/BF01957224
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01957224